To recover your password please fill in your email address
Please fill in below form to create an account with us
MOST 15 SUBSTUDIES 33-34: DURVALUMAB PLUS ACALABRUTINIB
A single arm, open label, signal seeking, phase II trial of the activity of Durvalumab in combination with Acalabrutinib in patients with high-grade B cell lymphoma.
|
Trial Summary: |
The aim of this substudy is to assess the clinical activity of durvalumab and acalabrutinib in patients with high grade B cell lymphoma. |
|
Supported By: |
|
|
Eligibility: |
Adult patients with pathologically confirmed high grade B cell lymphoma enrolled in the MoST program for molecular screening are eligible for this study. |
|
Registration ID: |
ACTRN12621000507886 |
|
Participation: |
National |
|
Status: |
Recruiting |
|
Activation Date: |
24/08/2021 |
|
Chair: |
Professor Steven Lane |
|
Contact: |